These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 28474547)

  • 1. New Human Monoamine Oxidase A Inhibitors with Potential Anti- Depressant Activity: Design, Synthesis, Biological Screening and Evaluation of Pharmacological Activity.
    Evranos-Aksoz B; Ucar G; Tas ST; Aksoz E; Yelekci K; Erikci A; Sara Y; Iskit AB
    Comb Chem High Throughput Screen; 2017; 20(6):461-473. PubMed ID: 28474547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis and hMAO Inhibitory Screening of Novel 2-Pyrazoline Analogues.
    Evranos-Aksoz B; Ucar G; Yelekci K
    Comb Chem High Throughput Screen; 2017; 20(6):510-521. PubMed ID: 28474546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of some novel hydrazone and 2-pyrazoline derivatives: monoamine oxidase inhibitory activities and docking studies.
    Evranos-Aksöz B; Yabanoğlu-Çiftçi S; Uçar G; Yelekçi K; Ertan R
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3278-84. PubMed ID: 24986657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Screening of Human Monoamine Oxidase-A Inhibitor Effect of New 2-Pyrazoline and Hydrazone Derivatives.
    Evranos-Aksöz B; Baysal İ; Yabanoğlu-Çiftçi S; Djikic T; Yelekçi K; Uçar G; Ertan R
    Arch Pharm (Weinheim); 2015 Oct; 348(10):743-56. PubMed ID: 26293971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
    Salgin-Goksen U; Telli G; Erikci A; Dedecengiz E; Tel BC; Kaynak FB; Yelekci K; Ucar G; Gokhan-Kelekci N
    J Med Chem; 2021 Feb; 64(4):1989-2009. PubMed ID: 33533632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of oxindole derivatives as antidepressive agents.
    Suthar SK; Bansal S; Alam MM; Jaiswal V; Tiwari A; Chaudhary A; Alex AT; Joseph A
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5281-5. PubMed ID: 26428872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine oxidase inhibitory activity of 3,5-biaryl-4,5-dihydro-1H-pyrazole-1-carboxylate derivatives.
    Vishnu Nayak B; Ciftci-Yabanoglu S; Jadav SS; Jagrat M; Sinha BN; Ucar G; Jayaprakash V
    Eur J Med Chem; 2013 Nov; 69():762-7. PubMed ID: 24099995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of nitrocatechol chalcone and pyrazoline derivatives as inhibitors of catechol-O-methyltransferase and monoamine oxidase.
    Hitge R; Smit S; Petzer A; Petzer JP
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127188. PubMed ID: 32299731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrazoline Derivatives as Promising MAO-A Targeting Antidepressants: An Update.
    Choudhary D; Kaur R; Singh TG; Kumar B
    Curr Top Med Chem; 2024; 24(5):401-415. PubMed ID: 38318823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAO enzymes inhibitory activity of new benzimidazole derivatives including hydrazone and propargyl side chains.
    Can ÖD; Osmaniye D; Demir Özkay Ü; Sağlık BN; Levent S; Ilgın S; Baysal M; Özkay Y; Kaplancıklı ZA
    Eur J Med Chem; 2017 May; 131():92-106. PubMed ID: 28301816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies.
    Jagrat M; Behera J; Yabanoglu S; Ercan A; Ucar G; Sinha BN; Sankaran V; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4296-300. PubMed ID: 21680183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies.
    Karuppasamy M; Mahapatra M; Yabanoglu S; Ucar G; Sinha BN; Basu A; Mishra N; Sharon A; Kulandaivelu U; Jayaprakash V
    Bioorg Med Chem; 2010 Mar; 18(5):1875-81. PubMed ID: 20149663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute configuration and biological profile of pyrazoline enantiomers as MAO inhibitory activity.
    Goksen US; Sarigul S; Bultinck P; Herrebout W; Dogan I; Yelekci K; Ucar G; Gokhan Kelekci N
    Chirality; 2019 Jan; 31(1):21-33. PubMed ID: 30468523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (Thiazol-2-yl)hydrazone derivatives from acetylpyridines as dual inhibitors of MAO and AChE: synthesis, biological evaluation and molecular modeling studies.
    D'Ascenzio M; Chimenti P; Gidaro MC; De Monte C; De Vita D; Granese A; Scipione L; Di Santo R; Costa G; Alcaro S; Yáñez M; Carradori S
    J Enzyme Inhib Med Chem; 2015 Dec; 30(6):908-19. PubMed ID: 25807300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and monoamine oxidase inhibitory activities of some 3-(4-fluorophenyl)-5-aryl-n-substituted-4,5-dihydro-(1H)-pyrazole-1-carbothioamide derivatives.
    Koç GŞ; Tan OU; Uçar G; Yildirim E; Erol K; Palaska E
    Drug Res (Stuttg); 2014 Nov; 64(11):591-8. PubMed ID: 24452523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, Biochemistry, and Computational Studies of Brominated Thienyl Chalcones: A New Class of Reversible MAO-B Inhibitors.
    Mathew B; Haridas A; Uçar G; Baysal I; Joy M; Mathew GE; Lakshmanan B; Jayaprakash V
    ChemMedChem; 2016 Jun; 11(11):1161-71. PubMed ID: 27159243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of novel 2-pyrazoline-1-ethanone derivatives as selective MAO inhibitors.
    Tong X; Chen R; Zhang TT; Han Y; Tang WJ; Liu XH
    Bioorg Med Chem; 2015 Feb; 23(3):515-25. PubMed ID: 25541201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, and Evaluation of 2-Amino-6-nitrobenzothiazole-Derived Hydrazones as MAO Inhibitors: Role of the Methylene Spacer Group.
    Tripathi RK; Ayyannan SR
    ChemMedChem; 2016 Jul; 11(14):1551-67. PubMed ID: 27332045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and molecular modelling of novel substituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors.
    Chimenti F; Bolasco A; Manna F; Secci D; Chimenti P; Granese A; Befani O; Turini P; Alcaro S; Ortuso F
    Chem Biol Drug Des; 2006 Mar; 67(3):206-14. PubMed ID: 16611214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies.
    Sahoo A; Yabanoglu S; Sinha BN; Ucar G; Basu A; Jayaprakash V
    Bioorg Med Chem Lett; 2010 Jan; 20(1):132-6. PubMed ID: 19945874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.